Johnson & Johnson (NYSE:JNJ) was upgraded by equities research analysts at Vetr from a “sell” rating to a “hold” rating in a research note issued on Tuesday, October 24th. The firm currently has a $137.71 price objective on the stock. Vetr‘s price objective suggests a potential downside of 1.33% from the stock’s current price.
A number of other equities research analysts have also issued reports on the stock. Citigroup Inc. lifted their target price on shares of Johnson & Johnson from $140.00 to $149.00 and gave the company a “buy” rating in a research note on Monday, October 23rd. Credit Suisse Group set a $154.00 target price on shares of Johnson & Johnson and gave the company an “outperform” rating in a research note on Thursday, October 19th. Jefferies Group LLC lifted their price objective on shares of Johnson & Johnson from $157.00 to $160.00 and gave the company a “buy” rating in a research note on Monday, October 16th. Barclays PLC lifted their price objective on shares of Johnson & Johnson from $140.00 to $148.00 and gave the company an “equal weight” rating in a research note on Wednesday, October 18th. Finally, Cowen and Company reaffirmed an “outperform” rating and issued a $155.00 price objective (up previously from $147.00) on shares of Johnson & Johnson in a research note on Wednesday, October 18th. Four investment analysts have rated the stock with a sell rating, eight have given a hold rating and eleven have issued a buy rating to the company’s stock. The stock currently has an average rating of “Hold” and a consensus price target of $143.70.
Johnson & Johnson (NYSE JNJ) opened at $139.56 on Tuesday. The company has a debt-to-equity ratio of 0.36, a current ratio of 1.32 and a quick ratio of 1.02. The stock has a market cap of $374,930.72, a P/E ratio of 19.55, a price-to-earnings-growth ratio of 2.84 and a beta of 0.82. Johnson & Johnson has a 12-month low of $109.32 and a 12-month high of $144.35.
Johnson & Johnson (NYSE:JNJ) last posted its quarterly earnings data on Tuesday, October 17th. The company reported $1.90 earnings per share for the quarter, topping the consensus estimate of $1.80 by $0.10. Johnson & Johnson had a net margin of 21.28% and a return on equity of 27.38%. The firm had revenue of $19.65 billion for the quarter, compared to analysts’ expectations of $19.29 billion. During the same period in the previous year, the company posted $1.68 EPS. The company’s quarterly revenue was up 10.3% compared to the same quarter last year. equities analysts forecast that Johnson & Johnson will post 7.28 EPS for the current year.
TRADEMARK VIOLATION NOTICE: This article was posted by Dispatch Tribunal and is the property of of Dispatch Tribunal. If you are reading this article on another site, it was illegally copied and republished in violation of U.S. and international copyright & trademark laws. The original version of this article can be viewed at https://www.dispatchtribunal.com/2017/11/12/johnson-johnson-jnj-lifted-to-hold-at-vetr-inc.html.
A number of hedge funds and other institutional investors have recently made changes to their positions in the stock. Zeke Capital Advisors LLC lifted its holdings in Johnson & Johnson by 98.3% in the third quarter. Zeke Capital Advisors LLC now owns 60,479 shares of the company’s stock valued at $7,863,000 after buying an additional 29,978 shares during the period. Amalgamated Bank lifted its holdings in Johnson & Johnson by 1.9% in the third quarter. Amalgamated Bank now owns 312,043 shares of the company’s stock valued at $40,569,000 after buying an additional 5,712 shares during the period. Twin Capital Management Inc. lifted its holdings in Johnson & Johnson by 9.0% in the third quarter. Twin Capital Management Inc. now owns 278,900 shares of the company’s stock valued at $36,260,000 after buying an additional 23,010 shares during the period. Destination Wealth Management lifted its holdings in Johnson & Johnson by 1.6% in the third quarter. Destination Wealth Management now owns 196,500 shares of the company’s stock valued at $25,547,000 after buying an additional 3,136 shares during the period. Finally, Hartland & Co. LLC lifted its holdings in Johnson & Johnson by 30.1% in the third quarter. Hartland & Co. LLC now owns 64,441 shares of the company’s stock valued at $8,378,000 after buying an additional 14,925 shares during the period. Institutional investors and hedge funds own 66.06% of the company’s stock.
About Johnson & Johnson
Johnson & Johnson is a holding company, which is engaged in the research and development, manufacture and sale of a range of products in the healthcare field. It operates through three segments: Consumer, Pharmaceutical and Medical Devices. Its primary focus is products related to human health and well-being.
To view Vetr’s full report, visit Vetr’s official website.
Receive News & Ratings for Johnson & Johnson Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Johnson & Johnson and related companies with MarketBeat.com's FREE daily email newsletter.